AU2002364052B2 - Novel compositions and methods for cancer - Google Patents

Novel compositions and methods for cancer Download PDF

Info

Publication number
AU2002364052B2
AU2002364052B2 AU2002364052A AU2002364052A AU2002364052B2 AU 2002364052 B2 AU2002364052 B2 AU 2002364052B2 AU 2002364052 A AU2002364052 A AU 2002364052A AU 2002364052 A AU2002364052 A AU 2002364052A AU 2002364052 B2 AU2002364052 B2 AU 2002364052B2
Authority
AU
Australia
Prior art keywords
seq
protein
nucleic acid
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002364052A
Other languages
English (en)
Other versions
AU2002364052A1 (en
Inventor
Eric K. Engelhard
David W. Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagres Discovery Inc
Original Assignee
Sagres Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagres Discovery Inc filed Critical Sagres Discovery Inc
Publication of AU2002364052A1 publication Critical patent/AU2002364052A1/en
Application granted granted Critical
Publication of AU2002364052B2 publication Critical patent/AU2002364052B2/en
Priority to AU2008203436A priority Critical patent/AU2008203436A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
AU2002364052A 2001-12-20 2002-12-20 Novel compositions and methods for cancer Ceased AU2002364052B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203436A AU2008203436A1 (en) 2001-12-20 2008-07-31 Novel compositions and methods for cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/034,650 US20030216558A1 (en) 2000-12-22 2001-12-20 Novel compositions and methods for cancer
US10/034,650 2001-12-20
PCT/US2002/041776 WO2003053224A2 (en) 2001-12-20 2002-12-20 Novel compositions and methods for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203436A Division AU2008203436A1 (en) 2001-12-20 2008-07-31 Novel compositions and methods for cancer

Publications (2)

Publication Number Publication Date
AU2002364052A1 AU2002364052A1 (en) 2003-07-09
AU2002364052B2 true AU2002364052B2 (en) 2008-07-10

Family

ID=21877742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002364052A Ceased AU2002364052B2 (en) 2001-12-20 2002-12-20 Novel compositions and methods for cancer
AU2008203436A Withdrawn AU2008203436A1 (en) 2001-12-20 2008-07-31 Novel compositions and methods for cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008203436A Withdrawn AU2008203436A1 (en) 2001-12-20 2008-07-31 Novel compositions and methods for cancer

Country Status (6)

Country Link
US (1) US20030216558A1 (enExample)
EP (1) EP1469769A4 (enExample)
JP (1) JP2005512558A (enExample)
AU (2) AU2002364052B2 (enExample)
CA (1) CA2470844A1 (enExample)
WO (1) WO2003053224A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064377A1 (en) * 2000-11-06 2003-04-03 Yongming Sun Compositions and methods relating to prostate specific genes and proteins
US7820447B2 (en) * 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
GB0703887D0 (en) * 2007-02-28 2007-04-11 Bakhiet Abdelmoiz Immune system mediator
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
CN119757761A (zh) * 2024-12-16 2025-04-04 新疆医科大学第一附属医院 一种鉴别诊断活动性肺结核的生物标志物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2416292A1 (en) * 2000-06-29 2002-01-10 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
US20030044812A1 (en) * 2001-01-18 2003-03-06 Walker Michael G. Cell differentiation cDNAs induced by retinoic acid
DK1410011T3 (da) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US20030049623A1 (en) * 2001-07-18 2003-03-13 Shi Huang PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yang et al. "A family of novel PR-domain (PRDM) genes as candidate tumor supressors" GenCore database 23 July 2000 *

Also Published As

Publication number Publication date
WO2003053224A2 (en) 2003-07-03
EP1469769A4 (en) 2008-06-18
AU2008203436A1 (en) 2008-08-21
CA2470844A1 (en) 2003-07-03
US20030216558A1 (en) 2003-11-20
AU2002364052A1 (en) 2003-07-09
WO2003053224A3 (en) 2003-09-04
JP2005512558A (ja) 2005-05-12
EP1469769A2 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
US20020182586A1 (en) Novel compositions and methods for cancer
AU2002364052B2 (en) Novel compositions and methods for cancer
US20030194702A1 (en) Novel compositions and methods for cancer
US20030022255A1 (en) Novel compositions and methods for breast cancer
EP1587405A2 (en) Novel compositions and methods for cancer
AU2003220178A1 (en) Novel compositions and methods in cancer associated with altered expression of prlr
AU2003225826B2 (en) Novel compositions and methods in cancer associated with altered expression of MCM3AP
US20030099963A1 (en) Novel compositions and methods in cancer associated with altered expression of TBX21
AU2003225750C1 (en) Novel compositions and methods in cancer associated with altered expression of KCNJ9
AU2003218331B2 (en) Novel compositions and methods in cancer associated with altered expression of PRDM 11
AU2003230669C1 (en) Novel compositions and methods in cancer associated with altered expression of TBX21
AU2007240202A1 (en) Novel compositions and methods for cancer
AU2008202138A1 (en) Novel compositions and methods in cancer associated with altered expression of MCM3AP
AU2008207455A1 (en) Novel compositions and methods in cancer associated with altered expression of TBX21

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired